GPB Scientific develops the Curate Cell Processing System, a benchtop platform using Deterministic Cell Separation (DCS™) technology currently optimized for T‑cell isolation and downstream handling. The system aims to improve recovery, purity, and cell health to address cost, turnaround time, scalability, and clinical performance limitations in CAR‑T and TCR programs. GPB plans additional releases targeting other cell types (including stem cells), expanded use cases, disease states, and workflow paradigms. Early data cited by the company indicate improvements in cost, target cell harvest time, and cell quality. The company works with biopharma, cancer centers, research institutes, and universities to advance and commercialize the platform. Financially, GPB announced an additional $18 million in capital as part of a previously announced financing to support expanded placements of Curate into partner facilities and further platform development. GPB Scientific is a biomedical company developing breakthrough technologies for therapeutic cell production and bioprocessing, headquartered in Vista, Calif. and Richmond, Va., and led by CEO Mike Grisham. The company is advancing the Curate™ Cell Processing System, which utilizes proprietary microfluidic deterministic lateral displacement technology in a closed system. The Curate system has demonstrated the ability to deliver high yield and quality to process CAR-T, stem, and other cells while providing the throughput and scalability required for cell and gene therapies. GPB Scientific raised $25.5M in financing led by Vensana Capital with strategic participation from Amgen Ventures and ongoing participation from existing investors. The company intends to use the funds to drive clinical assessment, GMP production, and commercialization of the Curate system.

Total raised

$44M

Funding rounds

2

Latest round

Equity

Latest activity

May 2021